The aim of glaucoma treatment is to preserve visual function with a minimum of side effects at an affordable cost. The best “neuroprotector” available is the “lowering of intraocular pressure” and this is still the treatment of choice in attempting to arrest or retard the loss of retinal ganglion cells. Laser treatment of the trabecular meshwork (TM) for glaucoma has become widely accepted treatment modality. Selective Laser Trabeculoplasty (SLT) is a safe and effective outpatient procedure with minimal and transient side effects. It is a safe alternative to argon laser trabeculoplasty and studies show that SLT provides effective reduction in intraocular pressure also in eyes that had previous argon laser trabeculoplasty (ALT) treatment. By selectively targeting only the pigmented TM cells and avoiding collateral thermal damage to surrounding cells and structures, SLT avoids permanent scarring of the TM as occurs with ALT.